

## IN THE SPECIFICATION

Please replace paragraph 0002 with the following amended paragraph, which contains the issued US patent number of the related application. Please replace paragraphs 0063 and 0064 with the following amended paragraphs, in which the spelling of the registered trademark "Voranol" is corrected.

[0002] This invention relates to synthetic surgical adhesives/sealants and tissue bonds created by reacting the adhesive with living mammalian tissue, and more specifically, to a tissue cross-linking pre-polymer for the purpose of forming a tissue crosslinked bond. This application is a co-pending application with commonly assigned co-pending U.S. patent application Ser. No. 09/676,851 filed Sep. 29, 2000, now issued as US 6,524,327 on Feb. 25, 2003, and which is incorporated herein by reference in its entirety.

### Example 6

[0063] A tri-functional polyether polyol (~~marketed as~~ Veranol marketed as Voranol CP 1421 average MW of 1421 was reacted with BASF Luparnate T80-1 (80:20 2,4- and 2,6-toluenediisocyanate) (23-39%) to obtain a NCO-terminated hydrophilic prepolymer having a free NCO content of 3.1%.

### Example 7

[0064] A tri-functional polyether polyol Veranol Voranol CP 1421 average MW of 1421 was reacted with (commercially available) BASF Luparnate T80-1 (80:20 2,4- and 2,6-toluenediisocyanate) (23-39%) to obtain a NCO-terminated hydrophilic prepolymer having a free NCO content of 3.1%.